Target intelligence / Profile preview

Propionyl-CoA carboxylase alpha chain, mitochondrial (PCCA)

Target
PCCA
Molecular classification
Enzyme, Biotin-dependent carboxylase, Mitochondrial matrix protein
01

Overview

Propionyl-CoA carboxylase alpha chain, mitochondrial (PCCA), is the alpha subunit of a biotin-dependent mitochondrial enzyme critical for the carboxylation of propionyl-CoA to (S)-methylmalonyl-CoA, an essential step in the catabolism of odd-chain fatty acids and branched-chain amino acids. The enzyme is a heterododecamer, composed of six alpha (PCCA) and six beta (PCCB) subunits, and requires biotin as a cofactor. Mutations in PCCA cause propionic acidemia, an autosomal recessive inborn error of metabolism characterized by life-threatening episodes of metabolic acidosis and long-term neurological and systemic complications. While not currently a target for small molecule drugs, PCCA is fundamental to cellular intermediary metabolism and serves as a diagnostic marker in metabolic disease.

Other names
Propionyl-CoA carboxylase subunit alphaPCCase subunit alphaPropanoyl-CoA:carbon dioxide ligase subunit alphaPropionyl-CoA carboxylase alpha subunitPCCase alpha subunitpccA complementation groupPropionyl coenzyme A carboxylase, alpha polypeptide
02

Mechanism of action

No targeted pharmacological mechanism of action as a drug target. Disease management focuses on dietary restriction or removing propionyl-CoA substrate source.

03

Biological functions

Catabolism of odd-chain fatty acidsCatabolism of branched-chain amino acids (valine, isoleucine, methionine, threonine)Catalysis of carboxylation of propionyl-CoA to (S)-methylmalonyl-CoAParticipation in intermediary metabolism and gluconeogenesis
04

Disease associations

Inborn errors of metabolism (notably propionic acidemia)Organic acidemiasMitochondrial disease associations
05

Safety considerations

Loss-of-function mutations can cause severe metabolic acidosis, neurological damage, or death (propionic acidemia)No established small molecule therapies; off-target effects not a clinical concern at present
06

Interacting drugs

None with direct enzyme inhibition/activation indications in current clinical practice; dietary drugs, carnitine, and antibiotics (for gut flora, as secondary management) are sometimes used in clinical management of propionic acidemia, but these do not *interact* with PCCA directly
07

Biomarkers

Abnormal blood/urinary propionylcarnitine (C3) levelsAccumulation of propionic acid and its metabolites (e.g., methylcitrate, 3-hydroxypropionate) in blood or urineDecreased enzyme activity measured in fibroblasts or white blood cells for diagnosis

Beyond the preview

Go deeper on Propionyl-CoA carboxylase alpha chain, mitochondrial (PCCA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Propionyl-CoA carboxylase alpha chain, mitochondrial (PCCA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call